Cargando…

Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis

BACKGROUND: Targeted immunomodulators (TIMs), including biologic disease-modifying antirheumatic drugs (DMARDs) and JAK/STAT inhibitors, are effective therapies for rheumatoid arthritis (RA), but some patients fail to respond or lose response over time. This study estimated the real-world prevalence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strand, Vibeke, Tundia, Namita, Song, Yan, Macaulay, Dendy, Fuldeore, Mahesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397636/ https://www.ncbi.nlm.nih.gov/pubmed/29578852 http://dx.doi.org/10.18553/jmcp.2018.24.4.344

Ejemplares similares

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
por: Strand, Vibeke, et al.
Publicado: (2019)

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
por: Strand, Vibeke, et al.
Publicado: (2019)

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
por: Strand, Vibeke, et al.
Publicado: (2020)

Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE
por: Strand, Vibeke, et al.
Publicado: (2021)

Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
por: Bergman, Martin, et al.
Publicado: (2022)

Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
por: Bergman, Martin, et al.
Publicado: (2021)

Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
por: Bergman, Martin, et al.
Publicado: (2022)

Nomenclature and Traceability Debate for Biosimilars: Small-Molecule Surrogates Lend Support for Distinguishable Nonproprietary Names
por: Chao, Jingdong, et al.
Publicado: (2015)

Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY
por: Strand, Vibeke, et al.
Publicado: (2020)

Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data
por: Yamazaki, Kiyotaka, et al.
Publicado: (2019)

Direct and indirect resource use, healthcare costs and work force absence in patients with non‐infectious intermediate, posterior or panuveitis
por: Thorne, Jennifer E., et al.
Publicado: (2016)

Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
por: Strand, Vibeke, et al.
Publicado: (2015)

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
por: Strand, Vibeke, et al.
Publicado: (2017)

Healthcare Costs of Not Achieving Remission in Patients with Rheumatoid Arthritis in the United States: A Retrospective Cohort Study
por: Bergman, Martin, et al.
Publicado: (2021)

Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis
por: Pope, Janet, et al.
Publicado: (2020)

Authors’ Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis
por: Pope, Janet, et al.
Publicado: (2021)

The economic burden of inadequate consumption of vegetables and fruit in Canada
por: Ekwaru, John Paul, et al.
Publicado: (2016)

Randomized controlled trial design in rheumatoid arthritis: the past decade
por: Strand, Vibeke, et al.
Publicado: (2009)

Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
por: Strand, Vibeke, et al.
Publicado: (2016)

The long‐term direct and indirect economic burden among Parkinson's disease caregivers in the United States
por: Martinez‐Martin, Pablo, et al.
Publicado: (2018)

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)
por: Taylor, Peter C, et al.
Publicado: (2023)

The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis
por: Shafrin, Jason, et al.
Publicado: (2018)

Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate
por: Lee, Won-Seok, et al.
Publicado: (2016)

Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis
por: Fuldeore, Mahesh J, et al.
Publicado: (2017)

Impact of Rheumatoid Arthritis Disease Activity Test on Clinical Practice
por: Peabody, John W., et al.
Publicado: (2013)

Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis
por: Zhou, Zhou, et al.
Publicado: (2019)

Machine learning identifies a profile of inadequate responder to methotrexate in rheumatoid arthritis
por: Duquesne, Julien, et al.
Publicado: (2022)

Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis
por: Carini, Claudio, et al.
Publicado: (2018)

Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2020)

Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes
por: Taylor, Peter C., et al.
Publicado: (2022)

Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2
por: Strand, Vibeke, et al.
Publicado: (2021)

Repurposing traditional immunomodulators to target the inflammatory burden of atherosclerosis()
por: Fender, Anke C., et al.
Publicado: (2020)

Estimating the Economic Burden of Rheumatoid Arthritis in Taiwan Using the National Health Insurance Database
por: Wang, Bruce C. M., et al.
Publicado: (2016)

Characterization of a Subset of Patients With Rheumatoid Arthritis for Whom Current Management Strategies are Inadequate
por: Bradford, Claire M., et al.
Publicado: (2019)

Latent profile analysis approach to the relationship between patient and physician global assessments of rheumatoid arthritis activity
por: Karpouzas, George A, et al.
Publicado: (2018)

A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2023)

Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data
por: Gharaibeh, Mahdi, et al.
Publicado: (2020)

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes
por: Genovese, Mark C, et al.
Publicado: (2018)

Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy
por: Zeng, Xiaofeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mlpq5kb32ih7kb9re3g4mcgvde